Roche seems determined to develop a commanding position in the emerging molecular glue category, signing up to a $2 billion partnership with Monte Rosa Therapeutics that includes a $50 million ...

By tagging its antibody with a molecular key that unlocks the barrier, Roche’s trontinemab quickly permeates the brain. The ...

Swiss pharma giant Roche Holding AG RHHBY posted better-than-expected 2024 results and provided an encouraging outlook for 2025. Sales in 2024 totaled $68.7 billion, which beat the Zacks Consensus ...

The new test is compatible with Roche's cobas 5800, 6800, and 8800 molecular diagnostic analysers, which are widely used in hospitals and other clinical settings, without any need for upgrades.

“Rapid molecular point-of-care testing can revolutionise ... said Matt Sause, CEO Roche Diagnostics.

Roche has given two early-phase bispecifics ... The other axed Chugai candidate was SPYK04, a RAF-MEK molecular glue that the Japanese drugmaker removed (PDF) from its pipeline in October.

The cobas liat test aims to improve patient outcomes by offering rapid, accurate results in decentralized and community-based settings for patients at risk for chlamydia, gonorrhea, and Mycoplasma ...

J.P. Morgan analyst Richard Vosser maintained a Sell rating on Roche Holding AG (RHHVF – Research Report) today and set a price target of ...

said Matt Sause, CEO Roche Diagnostics. The cobas liat system utilises gold-standard PCR technology to provide results in 20 minutes or less. The cobas liat assays are CLIA waived*, enabling ...

“Rapid molecular point-of-care testing can revolutionise the clinical ... and contain further spread by providing timely diagnosis.” said Matt Sause, CEO Roche Diagnostics.